Private Companies in ApicHope Pharmaceutical Co., Ltd (SZSE:300723) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 5.2% Last Week
Private Companies in ApicHope Pharmaceutical Co., Ltd (SZSE:300723) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 5.2% Last Week
Key Insights
主要见解
- ApicHope Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
- 57% of the business is held by the top 2 shareholders
- Insiders own 19% of ApicHope Pharmaceutical
- 一品红制药公司的重要私人公司所有权表明,关键决策会受到来自更大公众股东的影响。
- 前2名股东持有57%的业务
- 内部人员拥有一品红制药公司19%的股份。
If you want to know who really controls ApicHope Pharmaceutical Co., Ltd (SZSE:300723), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are private companies with 44% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
如果你想知道谁真正控制了一品红制药公司(SZSE:300723),那你需要看一下它持股注册表的组成情况。拥有最大份额的群体是持有44%的私人公司。也就是说,如果股票上涨(或者出现下滑),这个群体将会获得最大的利益(或者遭受最大的损失)。
As a result, private companies were the biggest beneficiaries of last week's 5.2% gain.
因此,私人公司成为上周5.2%涨幅的最大受益者。
Let's delve deeper into each type of owner of ApicHope Pharmaceutical, beginning with the chart below.
让我们深入了解一品红制药公司的每种所有者类型,从下面的图表开始。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240712/0-776898561ffd96aed1728ae64c069b85-0-e2431b1af43facebfe38e58da6cd507f.png/big)
What Does The Institutional Ownership Tell Us About ApicHope Pharmaceutical?
机构持股关于一品红制药公司的信息。
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
机构通常在向自己的投资者报告时会针对一个基准进行衡量,因此一旦某只股票被纳入主要指数,他们通常会更加热衷于该股票。我们预计大多数公司都会有一些机构在登记簿上,尤其是那些正在增长的公司。
ApicHope Pharmaceutical already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see ApicHope Pharmaceutical's historic earnings and revenue below, but keep in mind there's always more to the story.
一品红制药公司已经有机构投资者在持股注册表上。的确,他们在公司中拥有可观的股份。这表明公司在投资社区中具有一定的可信度,但是最好谨慎依赖机构投资者所带来的所谓认可。他们也会犯错误。当多个机构拥有一只股票时,总会有抱团交易的风险。当这样的交易失败时,多方可能会竞相卖出股票。在一个没有成长历史的公司中,这种风险更高。你可以在下面查看一品红制药公司的历史收益和营业收入,但要记住,事情总有更多的内情。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240712/0-776898561ffd96aed1728ae64c069b85-1-6d822b72bbffc441293a7f7a8a735974.png/big)
We note that hedge funds don't have a meaningful investment in ApicHope Pharmaceutical. The company's largest shareholder is Guangdong Guangrun Group Co., Ltd., with ownership of 41%. In comparison, the second and third largest shareholders hold about 16% and 5.4% of the stock. Hanxiong Li, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.
我们注意到,对于一品红制药公司,对冲基金没有意义的投资。该公司最大的股东是广东广润集团有限公司,持股比例为41%。相比之下,第二大和第三大股东持有约16%和5.4%的股份。第二大股东李汉雄也恰好是首席执行官的职位。
A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 57% stake.
股权登记簿的更详细研究向我们表明,前两大股东通过其拥有的57%股份在该公司拥有重大持股。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
尽管研究公司机构所有权数据是有意义的,但了解分析师的情绪也很有意义,以了解市场的走向。因为有很多分析师正在跟踪这个股票,所以看看他们的预测可能是值得的。
Insider Ownership Of ApicHope Pharmaceutical
一品红制药公司的内部人员拥有相当大的比例。它市值仅为90亿元人民币,而内部人员则拥有自己名下17亿元人民币的股份。这是相当大的。大多数人会说这显示了与股东的良好一致性,尤其是在这样规模的公司中。你可以点击此处看看这些内部人员是否一直在买卖。
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间是不同的。我们的数据反映了个别内部人员,至少捕捉到了董事会成员。公司管理业务,但首席执行官即使是董事会成员也必须向董事会负责。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。
It seems insiders own a significant proportion of ApicHope Pharmaceutical Co., Ltd. It has a market capitalization of just CN¥9.0b, and insiders have CN¥1.7b worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.
一品红制药公司的公众股东,主要由个人投资者组成,拥有20%的所有权,对一品红制药公司产生了一定的影响力。虽然这种所有权的大小可能不足以影响他们的决策,但他们仍然可以对公司政策产生集体影响。
General Public Ownership
一般大众所有权
With a 20% ownership, the general public, mostly comprising of individual investors, have some degree of sway over ApicHope Pharmaceutical. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
我们的数据显示,私人公司持有公司股份的44%。从这个事实很难得出任何结论,因此应该研究这些私人公司的所有者是谁。有时,内部人员或其他相关方可能会通过单独的私人公司拥有上市公司的股份。
Private Company Ownership
私有公司的所有权
Our data indicates that Private Companies hold 44%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
尽管考虑拥有一家公司的各个团体是值得的,但还有更重要的因素。例子就是:我们发现了一品红制药公司的4个警示信号,你应该注意一下。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 4 warning signs for ApicHope Pharmaceutical you should be aware of.
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
但最终,决定该业务所有者将获得多大利益的是未来而非过去。因此,我们认为最好查看此免费报告,以了解分析师是否预测更光明的未来。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。